Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues

We are witnessing a paradigm shift in drug development and clinical practice to fight the novel coronavirus disease (COVID-19), and a number of clinical trials have been or are being testing various pharmacological approaches to counteract viral load and its complications such as cytokine storm. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatti, Milo, Turrini, Eleonora, Raschi, Emanuel, Sestili, Piero, Fimognari, Carmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401109/
https://www.ncbi.nlm.nih.gov/pubmed/34451835
http://dx.doi.org/10.3390/ph14080738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401109/
https://www.ncbi.nlm.nih.gov/pubmed/34451835
http://dx.doi.org/10.3390/ph14080738

Ejemplares similares